Clinical Trials Browser

Hodgkin Disease, Lymphoma, B-Cell

Recurrence, Lymphoma, Mantle-Cell

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Multiple Myeloma

Lymphoma, Follicular

Multiple Myeloma

Multiple Myeloma

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Leukemia, Plasma Cell, Multiple Myeloma

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma, Neoplasms

Multiple Myeloma

Multiple Myeloma

Lymphoma, B-Cell

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Lymphoma, Non-Hodgkin

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Recurrence, Lymphoma, Large B-Cell, Diffuse

Neoplasms, Plasma Cell

Lymphoma, Mantle-Cell

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Mantle-Cell

Multiple Myeloma

Lymphoma, B-Cell, Marginal Zone

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Lymphoma, Lymphoma, Follicular

Waldenstrom Macroglobulinemia

Lymphoma, B-Cell, Marginal Zone

Clinical Trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

ECLAT

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

HEME-18

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

FASTER

MASTER-2

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

HD10/DSMMXX

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

UltraFrailMM

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

IFM2021-01

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Pola-ZR2P in Previously Untreated DLBCL

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

REPIFIR

MTR²

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL

SBRT Plus Lenalidomide for Solitary Plasmacytoma: Phase II Trial

V-MIND

Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

ZGR

TALTEC

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

TAURUS

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

REFRACT

Ballondor

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma